Lori Lyons-Williams - 29 May 2025 Form 4 Insider Report for RAPT Therapeutics, Inc. (RAPT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Jun 2025, 17:02:19 UTC
Prior SEC filing
29 May 2024
Next SEC filing
26 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Rodney Young, Attorney-in-Fact
Filing notes and source

Key filing fact

Lori Lyons-Williams filed Form 4 for RAPT Therapeutics, Inc. (RAPT) on 02 Jun 2025.

Key facts

  • This page summarizes Lori Lyons-Williams's Form 4 filing for RAPT Therapeutics, Inc. (RAPT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Jun 2025, 17:02.

Change

  • Previous filing in this sequence was filed on 29 May 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001693564 Primary reporting owner

Lyons-Williams Lori

Relationship
Director
Address
C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO
Signature
/s/ Rodney Young, Attorney-in-Fact
Signature date
02 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAPT transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value
$0
Shares
+257,832
Change %
Price
$0.000000
Shares after
257,832
Date
29 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
257,832
Exercise price
$0.9300
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Option shall vest in 12 equal monthly installments from date of grant of May 29, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .